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Abstract
Cortisol is a steroid hormone relevant to immune function in horses and other species and shows a circadian rhythm. The
glucocorticoid dexamethasone suppresses cortisol in horses. Pituitary pars intermedia dysfunction (PPID) is a disease in
which the cortisol suppression mechanism through dexamethasone is challenged. Overnight dexamethasone suppression
test (DST) protocols are used to test the functioning of this mechanism and to establish a diagnosis for PPID. However,
existing DST protocols have been recognized to perform poorly in previous experimental studies, often indicating presence
of PPID in healthy horses. This study uses a pharmacokinetic/pharmacodynamic (PK/PD) modelling approach to analyse
the oscillatory cortisol response and its interaction with dexamethasone. Two existing DST protocols were then scrutinized
using model simulations with particular focus on their ability to avoid false positive outcomes. Using a Bayesian popu-
lation approach allowed for quantification of uncertainty and enabled predictions for a broader population of horses than
the underlying sample. Dose selection and sampling time point were both determined to have large influence on the number
of false positives. Advice on pitfalls in test protocols and directions for possible improvement of DST protocols were given.
The presented methodology is also easily extended to other clinical test protocols.
Keywords Cortisol  Dexamethasone suppression test  Bayesian inference  Oscillating baseline  Turnover model 
Inter-individual variability  NLME
Introduction
Dexamethasone and other glucocorticoids are commonly
used in equine medicine for the treatment of diseases and
clinical testing, e.g., the dexamethasone suppression test
(DST) [1–3]. In healthy horses, dexamethasone suppresses
the cortisol response [4, 5]. The mechanism is challenged
in horses affected by pituitary pars intermedia dysfunction
(PPID) [6]. PPID is an age-related degenerative disease
leading to a loss of dopaminergic neurons affecting the pars
intermedia of the pituitary gland [7]. Similarities of PPID
to Parkinson’s disease in humans have been found [8]. The
most prevalent clinical signs of PPID in horses are hair coat
abnormalities, laminitis and muscle atrophy [9]. The
prevalence of PPID in horses aged more than 15 years is
21% [10].
The idea behind the DST is to observe whether the
cortisol response is suppressed below a threshold after
dexamethasone administration [1]. Different test protocols
have been published under the name overnight DST [1, 11].
They differ in dexamethasone administration time as well
as waiting-time until cortisol measurement. Both are
designed as single-point observation test protocols which
have limitations, since DST results may indicate presence
of PPID in healthy individuals due to a circadian rhythm in
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cortisol production in addition to inter-individual vari-
ability [12]. In horses, plasma cortisol concentration dis-
plays an apparently symmetric circadian variation with
peak concentration in the morning and nadir concentration
in the afternoon/evening [13, 14].
Pharmacokinetic (PK) and pharmacodynamic (PD)
modelling is done to quantify the relationship between a
physiological response and drug exposure [15]. The dis-
position of dexamethasone in horses has been characterized
in several studies [12, 16–20]. The relationship between
dexamethasone and cortisol response has also been char-
acterised by turnover modelling with inhibition of a con-
stant [21] as well as an oscillating turnover rate [12]. Those
studies focused on modelling individual concentration–
time as well as response-time courses. Modelling studies
have not estimated potential variability between animals.
A non-linear mixed-effects (NLME) approach allows
simultaneous regression of all individuals and time courses
[22]. A merit of this technique is the estimation of inter-
individual variability (IIV) directly from data [23]. The use
of mixed effects models has historically not been exten-
sively used in veterinary science but recently has been
given more attention [24]. Mixed-effects models can be
formulated as hierarchical Bayesian models [25]. The
Bayesian approach allows for incorporation of prior
knowledge as well as modelling of all sources of variability
and uncertainty. This allows for explicit propagation of
uncertainty in parameter estimates and residual variability
to predictions made using the final adjusted model [22].
Including all sources of uncertainty and simulating pre-
dictions from the full model, as is straight-forward in the
Bayesian approach, increases the credibility of the pre-
dictions. Prior information about parameter estimates and
variability is available from an earlier study [12].
In this study, we sought to analyse data from a previous
study [12] by means of a NLME approach to investigate
the IIV. We then used the adjusted model to scrutinize DST
protocol designs, define weaknesses in two proposed test
protocols and give directions for test improvement.
Materials and methods
Experimental setup and analytical method
Six Standardbred horses (four mares and two geldings)
6–20 years old and weighing 430–584 kg were included in
the study and assigned to a randomised crossover design
including four treatments and four periods. Each treatment
started with an intravenous bolus dose immediately fol-
lowed by 3 h of constant rate infusion of dexamethasone
21-phosphate disodium salt (Dexadreson 2 mg mL-1,
Intervet AB, Sollentuna, Sweden). The dose levels were
(bolus ? infusion) 0.1 ? 0.07 lg kg-1, 1 ? 0.7 lg kg-1
and 10 ? 7 lg kg-1 dexamethasone. For the control level
0.9% saline was used. Before the bolus dose (time = 0) a
pre-dose blood sample was drawn. Additional blood sam-
ples were drawn during and after infusion at hours 1, 2, 3,
4, 5, 6, 9, 12, 18, 24, 36 and 48. A minimum of a 1 week
wash-out period was allowed between drug treatments. The
study was approved by the Ethics Committee for Animal
Experiments, Uppsala, Sweden (C333/11). Total plasma
dexamethasone and cortisol concentrations were analysed
and quantified using Ultra High Performance Liquid
Chromatography-Tandem Mass Spectrometry (UHPLC-
MS/MS). The analytical method was described before
elsewhere [21].
Dexamethasone exposure
A two-compartment model (Eq. 1, Fig. 1a) was fitted to
experimental dexamethasone-time course data.
Vc
dCp
dt
¼ InfðtÞ  Cl  Cp þ Cld Ct  Cp
 
; Cpð0Þ ¼ D
Vc
Vt
dCt
dt
¼ Cld Cp  Ct
 
; Ctð0Þ ¼ 0
8
><
>:
ð1Þ
Cp and Ct denote drug concentration in central (plasma)
and peripheral compartments. Vc, Vt, Cl and Cld denote,
respectively, the central and peripheral volumes, plasma
clearance and inter-compartmental distribution parameter.
Inf(t) represents the constant rate infusion regimen and D is
the bolus dose administered at time t = 0.
Cortisol turnover
Cortisol was modelled by a turnover model (Eqs. 2–4,
Fig. 1b).
dR
dt
¼ kinðtÞ  IðtÞ  koutR; Rð0Þ ¼ Reqðt ¼ 0;Cp; eq ¼ 0Þ
ð2Þ
R is cortisol concentration, kout the fractional turnover
rate and Req stands for the expression in Eq. 5. The oscil-
latory behaviour of turnover rate was modelled by Eq. 3.
Note that in the following x = 2p/24 h-1.
kinðtÞ ¼ kavg  1þ a  cos x ðt  t0Þð Þð Þ ð3Þ
kavg is positive and corresponds to the average turnover
rate. t0 is the phase shift between - 12 and 12 h, and a, a
number between 0 and 1, describes the amplitude of the
oscillations as a proportion of kavg. Choosing a this way
ensures positivity of the turnover rate for all choices of
parameters. The period was fixed at 24 h. The inhibitory
dexamethasone mechanism function was modelled as
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IðtÞ ¼ 1 Imax C
n
pðtÞ
ICn50 þ CnpðtÞ
; ð4Þ
where Imax is maximum inhibitory capacity, IC50 the
potency of dexamethasone and n is a Hill exponent. This
model is a modified version of the single cosine model
presented in [26].
Cortisol concentration under constant
dexamethasone exposure
An oscillating turnover rate leads to oscillating cortisol
concentration. Keeping dexamethasone exposure in Eq. 4
constant at a fixed concentration Cp, eq, the cortisol
response is given by
Reqðt;Cp; eqÞ ¼ Aþ B  cos x ðt  CÞð Þ ; ð5Þ
where
A ¼ kavg
kout
 1 Imax C
n
p; eq
ICn50 þ Cnp; eq
 !
;
B ¼ kavg  aﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
k2out þ x2
p  1 Imax C
n
p; eq
ICn50 þ Cnp; eq
 !
;
C ¼ 1
x
arctan
kout sinðxt0Þ þ x cosðxt0Þ
kout cosðxt0Þ  x sinðxt0Þ
 
:
ð6Þ
A describes the average cortisol response, B the ampli-
tude and C the phase shift of the oscillation. The model
predicts only changes in the average cortisol response and
amplitude due to changes in dexamethasone exposure. A
derivation of Req in Eq. 5 as well as for A, B and C in Eq. 6
can be found in the Appendix. The ideas are similar to the
calculations presented in Krzyzanski et al. [27].
Residual error variance model
Kinetic data was modelled on a log scale. For the drug
exposure model in Eq. 1 it was assumed that
log Cp tij
   ¼ log cCp tij
  þ eij: ð7Þ
For the cortisol response model in Eq. 2 a combined
error model with proportional and additive error was
assumed. This was described by
R tij
  ¼ R^ tij
 
1þ sð1Þij
 
þ sð2Þij : ð8Þ
Here, Cp(tij) and R(tij) are the jth measurement of the
plasma concentration of dexamethasone in the central
compartment and cortisol, respectively, measured for sub-
ject i at time point tij. cCpðtijÞ and R^ðtijÞ are the predicted
concentrations for subject i at time point tij. eij as well as
s
ð1Þ
ij and s
ð2Þ
ij were assumed to be normally distributed with
zero mean and respective standard deviations e as well as
r1 and r2.
Statistical parameter model
IIV was modelled by making the following assumptions
about the distribution of the parameters in Eqs. 1–4. The
process of deciding which parameters were modelled with
correlation is described in the Supplementary.
All parameters involved in the description of dexam-
ethasone exposure were modelled independently log-nor-
mally distributed, i.e.,
logðhÞLog-Normal ðl; s2Þ ;
lNormal ðm0; 1Þ ;
s Student-t ð4; s0; 0:25Þ ;
ð9Þ
Fig. 1 a Dexamethasone disposition model after the bolus ? constant rate infusion regimens. b Conceptual model of the cortisol turnover with
an oscillating baseline kin(t)
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where m0 and s0 are prior parameters and h stands for Cl,
Cld, Vc and Vt. Some parameters in the cortisol turnover
model were modelled with correlations as
log kavg
 
log koutð Þ
log IC50ð Þ
logit að Þ
logit
t0 þ 12h
24h
 
0
BBBBBB@
1
CCCCCCA
Normal l; Xð Þ; ð10Þ
where X = LDLT, D ¼ diagðs21; s22; s23; s24; s25Þ and L is a
lower-triangular matrix. In this representation the matrix
D contains the variances and LLT is the correlation matrix.
In addition
nNormal ðln; snÞ ;
ImaxLogit-Normal ðlImax ; sImaxÞ :
ð11Þ
Hyperparameters l in Eqs. 10, 11 and the diagonal
elements of D as well as s in Eq. 11 are distributed as
lNormal ðm0; vÞ ;
s Student-t ð4; s0; 0:25Þ ; s 0 :
ð12Þ
where m0 and s0 are prior parameters, v = 2.5 for hyper-
parameters related to a as well as t0, and v = 1 otherwise.
The three-parameter Student-t distributions used in Eqs. 9,
12 for non-negative s are truncated distributions.
The correlation matrix LLT was assumed to be dis-
tributed following a LKJ distribution [28] with concentra-
tion parameter 2. This is a prior for correlation matrices
where samples resemble the identity matrix more closely
for concentration parameters closer to 1. Residual-error-
model standard deviations e and r1 and r2 were assumed to
be positive and were given half-Cauchy prior distributions
[29] with scale 2.5. Prior parameters were estimated from a
meta-analysis of Ekstrand et al. [12] as described in the
Appendix.
Analysis of the dexamethasone suppression test
protocol
We simulated two different overnight DST protocols. Each
consisted of a dexamethasone administration time and a
sampling time on the following day. Cortisol concentration
is analysed in the sampled blood plasma and the result of
the DST is positive if concentration is above a prescribed
threshold. The protocols analysed more closely are
described in Dybdal et al. [1] (protocol A) and Frank et al.
[11] (protocol B). Both protocols assume administration of
40 lg kg-1 of dexamethasone. The protocols differ in
administration route. Protocol A assumes intramuscular
(im) administration whereas protocol B assumes intra-
venous (iv) administration. Test starting times were at 9.00
a.m. (protocol B) and 5 p.m. (protocol A). Plasma sampling
times for determination of cortisol concentration were after
19 h (protocol A) and 24 h (protocol B), respectively. In
both protocols, the test is positive (indicating sick indi-
viduals) if measured cortisol concentration is above a
threshold of 10 lg L-1.
The DST protocols were analysed in light of two dif-
ferent aspects. First, we performed a Monte Carlo study to
visualise cortisol time courses for horses subjected to each
protocol. A sample of 10,000 horses was simulated from
the adjusted model. For this, residual variance parameters
and hyper-parameters (N = 1000) were taken from the
estimated posterior parameter distribution. Then, individ-
ual parameters (N = 10) were simulated from hyper-pa-
rameters and the distributions in Eqs. 9–11.
Dexamethasone- and cortisol time courses were simulated
under the two test protocols for the new subjects using
Eqs. 1–4 as well as the measurement equation (Eq. 8). The
investigated protocols assume administration of
40 lg kg-1 dexamethasone and the aim of this simulation
was to determine whether this amount is necessary or if
lower doses could be sufficient. Predicted cortisol con-
centration at sampling time was then used for further
analysis.
These concentrations were then used in a second step to
investigate both the sensitivity of the test, i.e., the proba-
bility that the test is positive for a sick subject, as well as
the specificity of the test, i.e., the probability that the test is
negative for a healthy subject [30]. The distributions of
sensitivity and specificity were simulated through a com-
bination of Monte Carlo and analytical steps. See the Ap-
pendix for the formulas used. In horses with PPID the
mechanism for dexamethasone suppression of cortisol is
challenged [6]. To quantify sensitivity, simulations from
sick horses were needed. We hypothesized that dexam-
ethasone has no suppression effect on sick individuals and
therefore these horses were sampled at baseline. The
studies reporting protocol A and B [1, 11] determined
sensitivity and specificity experimentally and this analysis
aimed to investigate if model predicted and experimentally
determined values are aligned.
Numerical analysis and parameter estimation
The software Stan version 2.18.0 [31] was used for
parameter inference through the interface CmdStan. Stan
implements the NUTS sampler [32] that uses Hamiltonian
Monte Carlo (HMC) [33] for estimation of the posterior
parameter distribution and allows models with differential
equations. PK and PD parameters were estimated in two
stages. First, PK parameters in Eq. 1 were estimated. Each
individual’s PK parameters were then summarised and
fixed to the respective conditional mean. In a second stage,
78 Journal of Pharmacokinetics and Pharmacodynamics (2019) 46:75–87
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the PD parameters in Eqs. 2–4 were estimated. In each
stage, four Markov chains were started at random initial
parameters around the prior parameter means. Each chain
was run for 250 iterations in warm-up and sampling,
respectively. This led to a total of N = 1000 samples from
the posterior.
The convergence of the HMC algorithm was checked in
multiple ways. Numerical divergences during parameter
estimation were observed and appropriate choices about
parameter distributions were made and Stan settings were
tuned to reduce and avoid divergences [34]. The Gelman–
Rubin R^ statistic [35] and trace plots were used to ensure
proper mixing of the Markov chains. The effective sample
size [25] was observed to be at least 10% of total samples
size (N = 1000). The energy Bayesian fraction of missing
information (E-BFMI) [36] was checked to ensure that the
parameter space was properly and efficiently explored. No
external validation data was available and therefore inter-
nal model checking was performed through posterior pre-
dictive checks (PPCs) [25]. These visualisations are similar
to visual predictive checks (VPCs) [37]. However, PPCs
include parameter uncertainty by simulating the response
from the full estimated posterior distribution, whereas
VPCs omit this. Estimated parameters were summarised by
median and 95% credible intervals (CIs) [25]. Population
predicted ranges were calculated as described in the
Supplementary.
Results
Regression of experimental time courses
The drug exposure model captured dexamethasone expo-
sure across three orders of magnitude (Figs. 2, S1). In
general, within and between subject variability in the
dexamethasone time courses were low, which suggests that
exposure of dexamethasone does not confound the cortisol
response. Observed and regressed dexamethasone-time
courses following the three dosing regimens for a repre-
sentative horse are shown in Fig. 2. The final population
model parameters as well as their predicted population
range are shown in Table 1. Summaries of individual
parameters per horse are reported in the Supplementary
(Table S1).
The observed cortisol response was well captured by the
model (Figs. 2, S2). The largest variability in cortisol
response was observed in baseline data. Increasing expo-
sure to dexamethasone suppressed both the average cortisol
response and the amplitude of oscillations (Fig. 2), which
was furthermore captured by the model. The suppression of
cortisol by dexamethasone was almost complete, which is
also evident from the estimated values of Imax close to 1
(Table 2). The typical potency value was predicted to be
37 ng L-1 varying between 22 and 56 ng L-1, and the
half-life of the cortisol response (ln (2)/kout) was predicted
to be 2.0 h varying between 1.1 and 3.4 h. Observed and
regressed cortisol response-time courses following the
three dosing regimens and baseline for a representative
horse are shown in Fig. 2. The final population model
parameters as well as their predicted population range are
shown in Table 2. Summaries of individual parameters per
horse are reported in the Supplementary (Table S2).
Uncertainty in parameter estimates and IIV are included
in the Bayesian posterior distribution and were readily
analysed. Variability in typical values and IIV standard
deviation was directly estimable. Predicted population
ranges contain variability stemming from both uncertainty
in population parameters and variability from the distri-
butional assumptions in the section ‘‘Statistical parameter
model’’. Uncertainty in population parameters was mod-
erate with larger amounts of variability observed in Cld
(Table 1) as well as a, t0 and IC50 (Table 2). Uncertainty in
IIV standard deviations was comparably larger, with 95%
Fig. 2 Dexamethasone and cortisol time course data and model
predictions for a representative horse. Different dosing regimens are
indicated by colour and respective dosing amounts are shown in the
legend. Solid lines are time courses corresponding to the subject’s
average parameters. Uncertainty in predicted time-courses is shown
by shaded areas representing 95% of uncertainty
Journal of Pharmacokinetics and Pharmacodynamics (2019) 46:75–87 79
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credible intervals often spanning double the magnitude of
the median. For parameters in the dexamethasone model
IIV was estimated to be small, with most credible intervals
reaching close to zero. For Cl the smallest amount of
variability (less than 0.2) was estimated whereas estimates
for Cld were largest (less than 0.9). Predicted IIV for the
parameters in the cortisol model was larger, particularly for
parameters kavg, a and IC50, with credible intervals being
clearly bounded from below. Estimated IIV for other
parameters was considered to be small with most vari-
ability in the predicted population range stemming from
uncertainty in estimated typical values.
After initial test runs and analysis of possible correla-
tions between individual parameters, correlation estimates
were included for kavg, a, t0, kout and IC50. The resulting
estimates can be found in the Supplementary (Table S3).
Most correlation parameters showed only a slight if any
tendency towards the positive or negative. Results suggest
possible negative correlations between kavg and a, kout and
a, and IC50 and a, but high uncertainty makes the estimates
inconclusive.
Simulation of cortisol response
versus dexamethasone plasma concentration
Model simulations of the equilibrium dexamethasone-cor-
tisol response relationship (Fig. 3a), and the amplitude of
cortisol response (Fig. 3b) with increasing dexamethasone
concentrations show that at concentrations around the
potency value (about 20 to 50 ng L-1) small changes in
dexamethasone plasma concentration produce dispropor-
tionally large changes in cortisol response and amplitude.
At concentrations well above the potency value
([ 100 ng L-1) small changes in dexamethasone plasma
concentration produce small changes in cortisol response
and amplitude. Note the almost complete suppression of
cortisol response and its variability, with increasing dex-
amethasone concentrations.
Simulation of two overnight DST protocols
We simulated time courses for healthy horses at four dif-
ferent dose levels (10, 20, 30 and 40 lg kg-1 dexametha-
sone administered intravenously) following protocols A and
B. The resulting Fig. 4 shows predicted variability in pos-
sible time-courses resulting from IIV and parameter uncer-
tainty. Additionally, predicted time courses under protocolA
and B for the horses involved in this study are shown.
The variability in cortisol response around the threshold
value (10 lg L-1) proposed in Dybdal et al. [1] was high
after administration of 10 lg kg-1 but decreased steadily
for increasing dose levels (Fig. 4). After administration of
the 40 lg kg-1 dose variability in cortisol response 19 h
after drug administration was lower than after the three
lower doses. The model-predicted cortisol response shows
that, even after the highest dose, individuals from a healthy
population might have cortisol plasma concentrations
greater than 10 lg L-1 at sampling time.
Systematic differences between the simulations of pro-
tocol A and B are shown in Fig. 4. Following protocol A,
dexamethasone is administered at 17.00 o’clock, which
coincides with cortisol decrease following the model-pre-
dicted circadian rhythm. Protocol B assumes administra-
tion at 9.00 o’clock which coincides with a peak in
Table 1 Estimated population
parameters, the IIV standard
deviation and predicted
population range for the
dexamethasone model
Parameter (unit) Typical valuea IIV std. dev.a Predicted population rangea
Cl (L h-1 kg-1) 0.50 (0.43, 0.56) 0.071 (0.0036, 0.22) 0.50 (0.39, 0.63)
Cld (L h
-1 kg-1) 0.16 (0.078, 0.33) 0.40 (0.032, 0.86) 0.16 (0.049, 0.55)
Vc (L kg
-1) 1.2 (0.74, 1.7) 0.15 (0.013, 0.48) 1.2 (0.62, 2.1)
Vt (L kg
-1) 0.76 (0.52, 1.0) 0.14 (0.013, 0.48) 0.76 (0.42, 1.3)
aValues reported as median and 95% credible interval
Table 2 Estimated population
parameters, the IIV standard
deviation and predicted
population range for the cortisol
model
Parameter (unit) Typical valuea IIV std. dev.a Predicted population rangea
kavg (lg L
-1 h-1) 15 (11, 22) 0.36 (0.15, 0.67) 15 (6.4, 37)
a (unitless) 0.30 (0.13, 0.58) 1.1 (0.77, 1.7) 0.31 (0.035, 0.85)
t0 (h) - 2.9 (- 4.3, - 1.3) 0.12 (0.0052, 0.37) - 3.0 (- 5.1, - 0.095)
kout (h
-1) 0.34 (0.27, 0.46) 0.20 (0.080, 0.45) 0.34 (0.20, 0.62)
Imax (unitless) 0.99 (0.97, 1.0) 0.41 (0.050, 0.96) 0.94 (0.81, 0.98)
IC50 (ng L
-1) 37 (22, 56) 0.56 (0.20, 0.97) 37 (9.1, 130)
n (unitless) 2.3 (1.5, 3.4) 0.39 (0.062, 0.99) 2.4 (1.1, 3.8)
aValues reported as median and 95% credible interval
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predicted cortisol concentration. As can also be seen from
the individual predictions (Fig. 4), cortisol concentrations
at administration time are generally lower following pro-
tocol A than B. At sampling time, 19 h (protocol A) or
24 h (protocol B) after administration, predicted concen-
trations for protocol A were consistently lower than for
protocol B. However, differences grew smaller with
increasing dexamethasone administration. For the highest
dose (40 lg kg-1), remaining dexamethasone concentra-
tion in blood plasma was predicted to 309 ng L-1 (varying
between 101 to 694 ng L-1) at sampling time for protocol
A and 155 ng L-1 (varying between 34 to 391 ng L-1) at
sampling time for protocol B. Suppressed cortisol con-
centration after administration of the largest dose of dex-
amethasone (40 lg kg-1) was lowest roughly between 5.00
o’clock and 12.00 o’clock for protocol A and 19.00 o’clock
and 3.00 o’clock for protocol B (Fig. 4).
Prediction of sensitivity and specificity
for overnight DST protocols
Sensitivity and specificity were predicted through Monte
Carlo simulations.All results are reported asmedian (95%CI).
For protocol A, a sensitivity of 99.1% (93.1% to 99.7%) and a
specificity of 83.4% (63.3% to 99.7%) were predicted. For
protocol B, a sensitivity of 99.2% (94.2% to 99.8%) and a
specificity of 77.8% (52.8% to 96.8%) were predicted. Sen-
sitivities for bothprotocols turnedout equal.Specificity tended
towards lower values for protocol B but there is no substantial
difference, given the spread of the credible intervals.
Discussion
In this study, we used an NLME approach to investigate the
IIV in dexamethasone exposure and cortisol response in
horses. The aim was to use the adjusted model to scrutinize
DST protocol designs. We analysed two proposed test
protocols through simulation, found systematic differences
in resulting cortisol time courses and predicted sensitivity
and specificity for each protocol.
The PK/PD model used in this study was based on a
previously published model (originally published in [26]
and used in [12]). For the purpose of this work, some parts
of the original model were simplified and re-parametrised.
An analytical solution of the cortisol model equations
(Eqs. 2–4) was used to initialise the parameter estimation
(see Eq. 5). This was necessary since the cortisol response
model does not have a constant steady state, which is
typically used for initialisation. The calibrated model
(Eqs. 1, 2) mimicked the overall tendency of the experi-
mental data well. Individual PK parameter estimates
(Table S1) and most PD parameters (Table S2) agree with
previously reported values [12]. Parameter a was not
directly comparable, since a different parametrisation of
the model is used in this study. In comparison to Ekstrand
et al. [12], the model in this study does not use a second
delay compartment for the cortisol response. This affects
individual estimates for parameter kout which were sys-
tematically lower in this study, about half the previously
estimated values. We found no evidence in the data to
motivate the necessity of an additional delay compartment.
Parameters kavg, a and IC50 showed evidence of non-zero
IIV.
Large improvements in estimated precision for param-
eter n were achieved in this study. However, considerable
uncertainty in some estimated parameters remained, nota-
bly Cld, a, t0 and IC50. Dexamethasone exposure data
(Figs. 2, S1) suggest a two-compartment model, but the
influence of the second compartment is subtle, which
explains the large uncertainty in parameter estimates of
Cld. Parameters a and t0 are mostly informed by baseline
measurements, as their influence is diminished by dexam-
ethasone administration. However, as reported in the
Fig. 3 a Plot of the average response (A in Eq. 6). b Plot of the oscillation amplitude (B in Eq. 6). Variability is shown as shaded areas
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results section (Figs. 2, S2) irregular fluctuations in base-
line measurements confound the underlying oscillation of
the cortisol response, explaining the challenge in precise
estimation of these two parameters. Irregular fluctuations in
baseline measurements can be explained by handling stress
[38] as well as pulsatility in cortisol secretion [39].
The multiple sources of uncertainty, incorporation of
IIV as well as the aim to utilize the calibrated model for
prediction motivated our use of a Bayesian approach. The
resulting posterior parameter distribution includes the
general tendency of the estimated parameter values, as well
as variability in form of IIV and parameter uncertainty.
When IIV is included through the framework of NLME,
parameter estimation can get more robust, since parameter
estimates for one subject are informed by estimates of other
subjects [22]. This can be seen in parameter n, which was
estimated with much higher precision in this study than in
Ekstrand et al. [12]. This holds for the Bayesian approach
as well as the maximum likelihood approach. However,
explicit inclusion of parameter uncertainty, when using a
Bayesian approach, allows for straight forward model
prediction, despite some remaining parameter uncertainty
[25].
One clinically relevant application of modelling the
cortisol response is evaluation of DST protocols. The
overnight DST is commonly used when testing for PPID.
Fig. 4 Simulated time courses
including model-predicted
variability for healthy horses
undergoing the DST protocols
A and B with the modification
of varying the test dose of 10,
20, 30 and 40 lg kg-1
dexamethasone. The black
dashed line represents the
threshold of 10 lg kg-1
proposed by Dybdal et al. [1].
Arrows indicate time for drug
administration at 9.00 o’clock
(protocol B) or 17.00 o’clock
(protocol A) and blood sample
19 h (protocol A) or 24 h
(protocol B) after
administration. Parameter
uncertainty and IIV are
incorporated into simulations.
This variability is shown by
blue shaded areas representing
increasing amounts of
variability (see legend).
Predicted time courses for the
horses in this study are shown as
solid red lines (Color
figure online)
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Test protocols tend to be straight forward to be usable in
both equine-clinics as well as in the field and typically
involve only one or two samples. We investigated two
overnight DST protocols through simulations, including an
analysis of their sensitivity and specificity. Both protocols
define a negative outcome as suppressed cortisol response
to less than 10 lg L-1 in blood plasma 19 or 24 h after
administration of 40 lg kg-1 dexamethasone [1, 11]. In
our simulations dexamethasone plasma concentration at
sampling time was was predicted to be 101–694 ng L-1 for
protocol A and 34–391 ng L-1 for protocol B. This result
is consistent with experimental data [16, 17]. Concentra-
tion at sampling time was above potency (22–54 ng L-1)
for most individuals. However, there is a larger risk for
dexamethasone concentration to fall below the potency
value when following protocol B. Combined with the IIV
in cortisol response, not all healthy horses will fall below
the proposed threshold (Fig. 4).
All simulations were made under the assumption of
intravenous administration of dexamethasone. Dybdal et al.
[1] used intramuscular administration of dexamethasone.
As shown by Soma et al. [17], dexamethasone plasma
concentrations reach peak concentration after intramuscu-
lar administration with a slight time delay (about 15 min)
compared to intravenous administration. However, con-
centrations at times 19 ? h after administration, relevant
for DST protocols, are comparable after intravenous as
well as intramuscular administration. We therefore decided
that it is reasonable to compare our simulations with the
data published by Dybdal et al. [1].
For the purposes of model estimation only data from
healthy horses was available. To simulate sensitivity for
DST protocols A and B, we hypothesized that sick horses
do not respond to dexamethasone administration. Their
responses were therefore simulated at baseline. This was
motivated by the known mechanism that cortisol suppres-
sion through dexamethasone is challenged in horses
affected by PPID [6]. PPID also seems to lead to a
reduction in circadian rhythm and an increase in average
baseline concentrations [1]. However, numerical values
quantifying these latter differences for the race of horses
used in this study were not available. Incorporating these
changes into the hypothesis stated above would have
increased the predicted sensitivity, which was close to
100% already. To the best of our knowledge, there is no
finding about differences in dexamethasone kinetics
between healthy horses and those affected by PPID.
Sensitivity and specificity were determined through
simulation for both protocols. The predicted specificity for
protocol A, Dybdal et al. [1] reporting 100% specificity,
was 63.3% to 99.7% and for protocol B, Frank et al. [11]
reporting 76% specificity, it was 52.8% to 96.8%. The
consistency between experimentally determined results and
our simulations makes us confident that our model captured
the overall cortisol response in healthy horses well. Pre-
dicted sensitivity for protocol A, Dybdal et al. [1] reporting
100% sensitivity, was 93.1% to 99.7% and for protocol B,
Frank et al. [11] reporting 65% sensitivity, it was 94.2% to
99.8%. An explanation for the large discrepancy between
our simulation and the experimental result for protocol B
might be that our hypothesis only applies to a population of
horses with clinically advanced PPID [40]. Such a popu-
lation was considered by Dybdal et al. [1] and simulated
sensitivity for protocol A is in agreement with experi-
mental results. Future work might consider simulations of
horses in which maximum suppression is decreased, imi-
tating a mechanism that still reacts to dexamethasone
suppression but at a reduced intensity.
DST protocols A and B use different starting times
(afternoon vs. morning) and different waiting times until
cortisol sampling (19 h vs. 24 h). Simulations show that it
can be more effective to administer dexamethasone during
a descending phase in cortisol’s circadian rhythm (Fig. 4).
Also, cortisol’s circadian rhythm can interfere with the
effectiveness of dexamethasone suppression (Fig. 4, pro-
tocol B, upswing after suppression coincides with natural
upswing in cortisol production). However, no substantial
difference in test outcome between protocols A and B was
found in this study. A finding also consistent with a study
by Sojka et al. [41] that investigated the influence of
starting time on the DST and found no statistically sig-
nificant difference between starting in the morning or the
afternoon.
Simulations showed that a dose of 40 lg kg-1 dexam-
ethasone is necessary to conduct the current test protocols,
with lower doses leading to an increased number of false
positives (Fig. 4). Small changes in dose around the
potency value result in large reduction of cortisol average
baseline and amplitude (Fig. 3), but this diminishes quickly
for concentrations above the potency value. This has
implications on dose selection and sampling time points in
the DST. A dose-increment and consequently increased
plasma exposure will decrease the number of false positive
test results in healthy individuals. It is important to con-
sider that negative adverse effects from glucocorticoids,
e.g., hyperglycaemia, hyperinsulinemia and possibly
laminitis, are assumed to increase with higher doses
[42–44]. Shorter waiting time until sampling could further
decrease the number of false positives. Cortisol is sup-
pressed quickly by dexamethasone and peak suppression is
reached earlier than 19 ? h after administration (Fig. 4).
However, this could mean sampling in the late evening or
at night (between 19.00 o’clock to 3.00 o’clock for pro-
tocol B), which might be unacceptable in the field. Protocol
A has better potential for improvement since suppression is
at its maximum during early morning hours (between 5.00
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o’clock to 12.00 o’clock for protocol A). Existing protocols
show that practical applicability is an important factor in
their design.
Ideally, serial sampling would be used. An extended
sampling protocol with 2–3 additional samples would
provide more information about cortisol behaviour and
more reliable test results. Additional collection of an
unaffected cortisol baseline would allow estimation of the
typical cortisol response for the particular horse and allow
for an increase in the predictive power of the test. How-
ever, this is not a suitable strategy for clinical routine,
especially not in the field and the cost would also be
accepted in lower extent by the owners. Given the chal-
lenge of producing a protocol that clinicians can perform,
2–3 samples after drug administration is the maximum to
be collected. Therefore, some uncertainty in interpretation
of test results remains and the diagnosis must be based not
only on the test outcome.
Conclusion
Our study presents an improved model structure and
parameter estimates for cortisol concentration in horses
during intervention with dexamethasone. The use of non-
linear mixed effects modelling allowed estimation of
variation between individuals finding IIV in parameters
kavg, a and IC50. Using a Bayesian approach allowed
straight-forward propagation of uncertainty to simulations.
The adjusted model was successfully used to scrutinize
clinical test protocols through simulation. The model out-
put and simulations indicated the importance of dose
selection with doses below 40 lg kg-1 performing unfa-
vourably. Sampling time was also found to be of impor-
tance and simulations showed that waiting times in the
window 10 to 17 h could improve test performance. In
addition, it was found that administrating dexamethasone
in synchronisation with the down-swing in cortisol’s cir-
cadian rhythm can allow for a slight prolongation in
waiting time.
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Appendix
Cortisol concentration for constant
dexamethasone concentration
The solution to the cortisol model equations (Eqs. 2–4) can
be found analytically for constant dexamethasone concen-
tration Cp = Cp, eq.
Mathematically, Eq. 2 describes a first-order differential
equation driven by an external oscillation (the turnover
rate). Using methods described by Farkas [45], it can be
shown that there exists a unique oscillating solution to
Eq. 2. This solution will have the same period as the
driving turnover rate and any other solution will tend
towards this oscillating solution. Assume that the model
equations are solved by
ReqðtÞ ¼ aþ b  cosðx ðt  t0ÞÞ þ c  sinðx ðt  t0ÞÞ ;
ð13Þ
where x = 2p/24 h-1 and t0 is the phase shift in the
turnover rate (Eq. 3). Solving for a, b and c gives
a ¼ kavg
kout
 1 ImaxC
n
p; eq
ICn50 þ Cnp; eq
 !
;
b ¼ kavg  a  kout
k2out þ x2
 1 Imax C
n
p; eq
ICn50 þ Cnp; eq
 !
;
c ¼ kavg  a  x
k2out þ x2
 1 Imax C
n
p; eq
ICn50 þ Cnp; eq
 !
:
ð14Þ
To determine characteristic parameters for the equilib-
rium oscillation, it is more convenient to write Eq. 13 in
the form ReqðtÞ ¼ Aþ B cosðx ðt  CÞÞ where A, B and
C are as in Eq. 6. This representation can be found by
standard arguments for the sum of trigonometric functions.
It can be seen from these equations that A and B depend on
the drug concentration, while C does not.
Determination of prior parameters
Prior beliefs about means and variances for hierarchically
distributed parameters were quantified through a meta-
analysis of Ekstrand et al. [12]. Therein, point estimates of
parameter values and their relative precision (coefficient of
variation, CV) in percent were reported. If h is the reported
point estimate and CV its relative precision then standard
errors r were calculated as r = (CVh)/100. To arrive at an
estimate for the population mean and population variance
for a parameter, e.g., Cl, weighted averages of the point
84 Journal of Pharmacokinetics and Pharmacodynamics (2019) 46:75–87
123
estimates were formed. Each estimate was weighted by its
squared standard error. Let hi and ri be the estimate and
standard error determined for the ith horse. Then
l^ ¼
P6
i¼1
hi
r2
iP6
i¼1
1
r2
i
and x^2 ¼
P6
i¼1
h2i
r2
iP6
i¼1
1
r2
0
@
1
A l^2; ð15Þ
where l^ and x^2 are the population mean and variance,
respectively.
Parameters were modelled hierarchically either through
a log-normal distribution (e.g., Cl), a (scaled) logit-normal
distribution (for a, t0 and Imax) or a normal distribution (for
n). For all parameters the prior location parameters m0 and
s0 were determined by matching mean and variance of the
respective distribution with those in Eq. 15.
For a normal distribution l^ and x^2 can be used directly.
Analytical formulas for the mean and variance of the log-
normal distribution exist. It holds that
l ¼ exp mþ s
2
2
 
and x2
¼ exp s2  1   exp 2mþ s2 ; ð16Þ
where m and s are the location and scale parameters of the
log-normal distribution. l and x2 were matched with l^ and
x^2 in Eq. 15 to determine m and s. Values can be found in
the table below.
In case of the (scaled) logit-normal distribution no
closed-form solutions for mean and variance exist. There-
fore, moments were calculated by numerical integration
using SciPy’s fixed_quad function [46]. Numerical opti-
mization was used to determine location and scale
parameters. The difference between numerically approxi-
mated moments and those in Eq. 15 was used as a target
function. SciPy’s fsolve, which implements methods from
MINPACK [47], was used for numerical optimization. The
resulting optimized parameters were m and s. Values can
be found in the table below.
The parameter controlling the average turnover rate kavg
was not directly given by Ekstrand et al. [12]. Instead, the
parameter Rij = kavg, ij/kout, i for individual i and occasion
j was given.1 Note that the parameter kavg was allowed to
vary by experimental occasion in Ekstrand et al. [12]. In
the model presented herein, the parameter kavg was mod-
elled with IIV instead. Individual- and occasion-specific
parameter estimates for kavg, ij could easily be recovered as
kavg, ij = Rijkout, i. Relative precisions were used to calcu-
late the standard errors rRij and rkout;i of each individual-/
occasion-dependent estimate. Standard errors for kavg, ij
were then approximated by propagation of uncertainty [48]
rkavg;ij  kavg;ij
		 		
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
rRij
Rij
 2
þ rkout;i
kout;i
 2
s
: ð17Þ
Summing over all individuals and occasions, weighted
averages, as in Eq. 15, were formed. These were matched
with mean and variance of a log-normal distribution to get
location m and scale s for kavg. Values can be found in the
table below.
Location parameters m and s for prior distribution of
hyper-parameters l and s.
Calculation of simulation of sensitivity
and specificity
By sampling j = 1,…, M individual parameter vectors,
called hij for the ith set of hyper-parameters, sensitivity Se
(i)
and specificity Sp(i) can be calculated as
SeðiÞ  1
M
XM
j¼1
1 U 10 R^ðh
ðiÞ
j Þﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
R^ðhðiÞj Þ2r21 þ r22
q
0
B@
1
CA
2
64
3
75 ð18Þ
and
SpðiÞ  1
M
XM
j¼1
"
U
10 R^ðhðiÞj Þﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
R^ðhðiÞj Þ2r21 þ r22
q
0
B@
1
CA
þ U R^ðh
ðiÞ
j Þﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
R^ðhðiÞj Þ2r21 þ r22
q
0
B@
1
CA 1


:
ð19Þ
Here, U is the cumulative distribution function of the
standard normal distribution, and R^ðhðiÞj Þ is the predicted
cortisol measurement obtained in the DST. In the case of
sensitivity, sick subjects were simulated and R^ðhðiÞj Þ was
therefore predicted at baseline without drug. For speci-
ficity, healthy subjects were simulated and R^ðhðiÞj Þ was
predicted after administration of 40 lg kg-1 dexametha-
sone. Repeating this procedure for many sets of hyper-
Parameter h Cl Cld Vc Vt kavg a t0 kout Imax IC50 n
m0 - 0.71 - 1.7 - 0.21 - 0.15 3.0 - 0.82 - 0.71 - 0.56 1.6 - 4.1 0.75
s0 0.064 0.46 0.27 0.16 0.46 0.98 0.10 0.26 0.34 0.73 0.36
1 R0 to R3 in [12], dependent on the occasion.
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parameters and a reasonably high value of M leads to a
distribution for sensitivity and specificity, which can be
summarised by median and credible interval. A derivation
of Eqs. 18, 19 is given in the Supplementary.
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